Incyte Corp Ltd

Most Recent

  • uploads///BGNE
    Company & Industry Overviews

    Do Analysts See Any Upside in BeiGene Stock?

    Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    A Look at Incyte’s Valuation as of May 25

    Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///pill _
    Company & Industry Overviews

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    What Do Analysts Recommend for United Therapeutics?

    23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”

    By Margaret Patrick
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Alexion Continues to Rise on FDA’s Approval of Kanuma

    Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Olumiant Could Boost Incyte’s Revenues

    In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis.

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    Incyte Was a Star Performer from August 10–17, 2015

    By market cap size, Incyte (INCY) is among the top ten holdings of the SPDR S&P Biotech ETF (XBI). Incyte has a weight of 1.22% in XBI’s portfolio.

    By Peter Neil
  • uploads///cells _
    Company & Industry Overviews

    Taking Stock of BeiGene’s Latest Performance

    BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    Analysts Expect Incyte to Report Revenue Growth in Third Quarter

    Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Shire’s Quarterly Revenue Trend

    Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.

    By Mike Benson
  • uploads///laboratory _
    Company & Industry Overviews

    A Look at Incyte’s Valuation on August 22

    On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.

    By Mike Benson
  • uploads///syringe _
    Earnings Report

    Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates

    Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.

    By Mike Benson
  • uploads///blood _
    Company & Industry Overviews

    Why Advaxis Stock Is Soaring Today

    Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Incyte’s Valuations on July 6

    Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares

    Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.

    By Mike Benson
  • uploads///gAINERS
    Company & Industry Overviews

    Nektar Therapeutics Closed Higher on June 14

    Nektar Therapeutics, which is an American biopharmaceutical company, was the S&P 500’s top performer on June 14.

    By Val Kensington
  • uploads///Chart
    Company & Industry Overviews

    Intellia Therapeutics Stock Fell 9.8% on Monday

    On June 11, Intellia stock fell 9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.

    By Mike Benson
  • uploads///gAINERS
    Company & Industry Overviews

    Incyte: S&P 500’s Top Gainer on April 12

    Incyte was the S&P 500’s top gainer on April 12. On April 12, Incyte gained 5.3% and closed the day at $69.83.

    By Val Kensington
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis’s 3Q17 Revenue Stream

    Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Incyte’s Collaborations and Developments in 4Q17

    Incyte (INCY) has a well-established distribution network in the United States and sells its products Jakafi and Iclusig in the country through its own network.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Incyte’s Jakafi Performed in 3Q17

    Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Was Incyte’s Revenue Stream in 3Q17?

    Incyte’s total product royalty revenue was $44.5 million in 3Q17, a rise compared to $29.6 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How’s Incyte’s Valuation in January 2018?

    Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.

    By Mike Benson
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in November 2017

    In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.

    By Daniel Collins
  • uploads///Analysts reco
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in August 2017

    In April 2017, United Therapeutics (UTHR) and 3D Systems (DDD) declared their plans to develop solid organ scaffolds for human transplants.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    What’s Ionis Pharmaceuticals’ Valuation?

    Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Incyte Had These Key Collaborations and Developments in 2Q17

    Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Inside Incyte’s Jakafi Performance in 2Q17

    Incyte’s Jakafi is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Incyte’s 2Q17 Revenue Stream

    Incyte’s 2Q17 revenue growth was driven by the increased demand for Jakafi.

    By Mike Benson
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in June 2017

    Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”

    By Daniel Collins
  • uploads///Chart  Keytruda
    Company & Industry Overviews

    Keytruda’s Developments in June 2017

    On June 12, 2017, Merck released updated data for Keytruda’s two phase III studies—KEYNOTE-183 and KEYNOTE-185—which evaluate Keytruda in combination with other drugs for the treatment of multiple myeloma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Investor Update: Incyte’s Key Developments in 1Q17

    Incyte (INCY) distributes its key drug Jakafi through its own network of specialty pharmacy providers and wholesalers in the US.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Incyte’s Product Portfolio Look in 1Q17?

    Incyte’s (INCY) product portfolio includes oncology and non-oncology drugs.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Incyte’s Valuation Has Changed since 1Q17 Results

    Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Changes in Ionis Pharmaceuticals’ Valuation after 1Q17

    In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we’ll look at its valuation since 1Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue

    Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuation Compared to Its Peers

    According to March 20, 2017, data, Ionis stock has risen 4.1% over the last 12 months.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Valeant’s Net Profit Margins Expected to Narrow in 2017

    Net profit margins Valeant Pharmaceuticals (VRX) has projected its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) to fall $3.6 billion–$3.7 billion. Besides lower revenue, the company will also have to bear $1.9 billion in cash interest in 2017, which includes $100 million in amortized deferred financing costs. Wall Street analysts have projected that […]

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    A Look at Incyte’s Product Portfolio

    Incyte has classified its oncology product portfolio into targeted anti-cancer therapies and immuno-oncology or immunotherapies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Performance of Incyte’s Jakafi in the United States

    Revenues for Jakafi rose more than 42.0% to $852.8 million in 2016, from $601.0 million in 2015.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why These Collaborations Are Important to Incyte

    Incyte’s (INCY) Jakafi is distributed in the US markets through its network of specialty pharmacy providers and wholesalers for direct delivery to patients or patients’ pharmacies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s in Incyte’s Product Portfolio?

    Incyte’s (INCY) product portfolio includes drugs for oncology as well as other areas.

    By Mike Benson
  • uploads///acq flexibility
    Company & Industry Overviews

    How Could Gilead Sciences Restore Its Growth?

    With its continuous revenue fall, Gilead Sciences (GILD) could opt to restore its growth through acquisitions.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Incyte’s Profitability Improves, Allowing for Revised Guidance

    Incyte (INCY) reported revenues of $246.3 million in 2Q16, an increase of 51% compared to $163 million in 2Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Incyte’s Product Portfolio Includes Potentially Lucrative Drugs

    Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. It includes targeted therapies as well as immunotherapies.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Expects to Commercialize Selective JAK1 Inhibitor ABT-494

    Currently being tested in six Phase 3 trials, ABT-494 is expected to be a significant improvement in the standard of care for rheumatoid arthritis.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    How Are XBI’s Holdings’ Moving Averages Trending?

    On June 8, 2016, 77% of XBI’s stocks were trading above their 20-day moving averages, 69% were trading above their 50-day moving averages, and 69% were trading above their 100-day moving averages.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    An Inside Look at Incyte’s Product Portfolio

    Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. For oncology, its product portfolio includes targeted therapies as well as immunotherapies.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Shire’s Shareholders Approve Baxalta Merger: What’s Next?

    Shire (SHPG) performed the worst among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) on May 27, 2016.

    By Peter Neil
  • Company & Industry Overviews

    Information Technology Stocks Made a Forgettable 1Q16 for IEOAX

    The Ivy European Opportunities Fund – Class A (IEOAX) fell a sharp 6.8% in 1Q16, placing it firmly at the bottom of the pack of 12 funds in this review.

    By David Ashworth
  • Company & Industry Overviews

    Consumer Discretionary Drove Down OLGAX’s Returns in 1Q16

    OLGAX fell 6.4% in 1Q16. OLGAX fell 3.7% in the one-year period ended March 2016 and ranked ninth among its peer group.

    By David Ashworth
  • uploads///Chart
    Company & Industry Overviews

    Incyte Continues Its Growth Spree in 2015

    Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Incyte’s Valuation Compare to Peers?

    Incyte, a Delaware-based biopharmaceutical company, is focused on developing and commercializing oncology products to cater to unmet medical needs.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    How Have IBB’s Large-Cap Stocks Performed?

    IBB has approximately 14 large-capitalization stocks in its portfolio with a market capitalization of more than $10 billion as of February 19, 2016.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Allergan Drives the Performance of XLV’s Top Ten Holdings

    Allergan gained 14.9% for the week ended October 30, 2015. The company’s stocks gained on the news of a possible merger with Pfizer.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    BioMarin Falls 16.81% in Week Ended September 25

    BioMarin Pharmaceutical (BMRN) fell 16.81% and closed at $108.69 last week. That’s below the 20-day, 50-day, and 100-day moving averages. The 14-day RSI was 28, or oversold territory.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Top Ten XBI Stocks by Market Cap Outperform August 25–31

    The top ten stocks of the SPDR S&P Biotech ETF (XBI) outperformed the top ten stocks of the iShares Nasdaq Biotechnology ETF (IBB) and the Health Care Select Sector SPDR ETF (XLV) for August 25–31.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.